Biotinylated Monoclonal Anti-IFNγ antibody, Mouse IgG1 (13E6H6) (Cat. No. IFN-BS138) captured on CM5 chip via anti-mouse antibodies surface can bind ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) with an affinity constant of 1.28 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Monoclonal Anti-IFNγ antibody, Mouse IgG2a (8C5F8) (Cat. No. IFN-S120) captured on CM5 chip via anti-mouse antibodies surface can bind ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) with an affinity constant of 0.933 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cadi-05 | Cadi-05 | Approved | National Institute Of Allergy And Infectious Diseases (Niaid) | Immuvac, Leprovac, Mycidac-C | India | Carcinoma, Non-Small-Cell Lung; Leprosy | null | 1998-01-01 | Leprosy; Carcinoma, Non-Small-Cell Lung | Details |
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | HIV Infections; Spondylitis, Ankylosing; Myelodysplastic Syndromes; Idiopathic Pulmonary Fibrosis; Multiple Myeloma; HIV Wasting Syndrome; Erythema Nodosum; Leprosy, Lepromatous; Carcinoma, Hepatocellular | Details |
Emapalumab | NI-0501 | Approved | Novimmune | Gamifant | United States | Lymphohistiocytosis, Hemophagocytic | Novimmune Sa | 2018-11-20 | Still's Disease, Adult-Onset; Macrophage Activation Syndrome; Rare Diseases; Arthritis, Juvenile; Immune System Diseases; Lupus Erythematosus, Systemic; Lymphohistiocytosis, Hemophagocytic | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
PDS-0101 | PDS-0101B; PDS-0101C; PDS-0101; PDS-0101A; PDS-101 | Phase 2 Clinical | Pds Biotechnology Corporation, Merck Serono | Head and Neck Neoplasms; Papillomavirus Infections; Anal intraepithelial neoplasia; Cervical Intraepithelial Neoplasia; Oropharyngeal Neoplasms; Uterine Cervical Neoplasms | Details |
PP-001 | PP-001 | Phase 2 Clinical | 4sc Ag | Keratoconjunctivitis; Uveitis | Details |
Recombinant human interferon gamma adenovirus injection | Phase 1 Clinical | Guangzhou Dabo Biological Products Co Ltd | Liver Neoplasms; Nasopharyngeal Neoplasms | Details | |
OCH-NCNP1 | OCH-NCNP1 | Phase 2 Clinical | Keio University | Multiple Sclerosis; Crohn Disease | Details |
Tadekinig alfa (AB2 Bio) | Phase 3 Clinical | Ab2 Bio | Macrophage Activation Syndrome; Immune System Diseases | Details | |
Vidofludimus | 4SC-101; SC-12267 | Phase 2 Clinical | 4sc Ag | Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease | Details |
SP-002 | SP-002; ASN-002; TG-1042 | Phase 2 Clinical | Lymphoma, B-Cell; Carcinoma, Basal Cell; Skin Neoplasms; Basal Cell Nevus Syndrome | Details |
This web search service is supported by Google Inc.